AST

The American Society of Transplantation Announces Dr. Joren C. Madsen as President

...setts General Hospital. He has been very active in ast serving as a Councilor-at-Large from 2005-2008, an... "I am honored to have the opportunity to lead the ast and to work with my fellow board members who repre...ly regarded society," said Dr. Madsen. About ast The American Society of Transplantation is an i...

AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives

...n several important activities: ast discussed healthcare reform initiatives with the H...ederal agencies. ast also delivered endorsement letters and expressed t...f Transplantation. ast leaders met with the office of Congressman Diana D...

Country Star Phil Vassar to Perform at Transplantation Fundraiser

...creasing transplant awareness," added Murphy. ast is dedicated to research, education and patient ca...ing an organ transplant, but by raising awareness, ast hopes to lower this number. Reserve Tickets...chusetts Ave. in Boston. Proceeds will benefit the ast endowment, created to support in perpetuity the...

AST President-Elect Joren Madsen Attends Regional White House Forum on Health Care Reform

...sing issues. I commend President Obama for bringing this issue to the forefront and eliciting feedback from a wide range of participants." About ast The American Society of Transplantation is an international organization of transplant professionals dedicated to advancing the field of transpl...

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US

...dditional Important Safety Information for TYKERB Hepatotoxicity - TYKERB has been associated with hepatotoxicity. Hepatotoxicity (ALT or ast >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of pat...

Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of Greater Than 3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who co...

Improved Ability to Predict Who is at Risk for Falling in SNFs and ALFs

... Physical Therapy Programs along with improved predictive techniques reported by Oxford University in September of 2008. These techniques, known as ast (Alternate Step Test), STS-5 (Sit to Stand 5 times) and the SMWT (Six Meter Walk Test) were used in a multi-year study conducted by researchers a...

American Society of Transplantation to Host Boston Pops and the Redford Family on May 30th to Raise Transplant Awareness

...husetts, Ave. in Boston. Proceeds will benefit the ast endowment, created to support in perpetuity the ast research grant portfolio, the training of transpla...ational outreach program for youth. About ast ...

CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume sub...

ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System

...e, and was developed to use the same affordable test strips as the downloadable GLUCOCARD(R) 01 system that launched in 2008. GLUCOCARD(R) 01-mini has ast and features pre/post meal flags. Most notable, the GLUCOCARD(R) 01-mini is the only system on the market that features interchangeable faceplates so ...

More>>

AST in Medical Technology

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... trials." In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean ast and ALT levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, ast elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopeni...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume sub...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume sub...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

...following statements: Raptor's and UC San Diego's ability to complete the clinical trial in NASH patients, cysteamine's ability to treat NASH, ALT and ast as a biomarker to determine the efficacy of a treatment for NASH, Raptor's ability to further develop cysteamine in NASH and other indications. These ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... headache and vomiting (limited duration and amenable to supportive care). The few drug-related Grade 3 and 4 toxicities (including fatigue, increased ast and headache, two patients each) were manageable and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities c...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...on adverse events (AEs) in the combination arm versus the monotherapy arm were diarrhea (67 percent vs. 58 percent), rash (28 percent vs. 29 percent), ast increase (32 percent vs. 16 percent), ALT increase (30 percent vs. 16 percent), nausea (29 percent vs. 16 percent), hypertension (26 percent vs. 4 per...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes de...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes de...

Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decr...

More>>